A Study of Orelabrutinib in Patients With ITP

NCT05124028 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

10

Enrollment

OTHER

Sponsor class

Conditions

Immune Thrombocytopenia

Interventions

DRUG: Orelabrutinib

Sponsor

Peking University People's Hospital